Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

Video

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

IMMU-132 is an anti—TROP-2 antibody-drug conjugate comprised of SN-38. Regarding safety, the agent is not as toxic compared with other antibody-drug conjugates, Tagawa explains. In a phase I/II study, grade 3 neutropenia was observed in patients who received IMMU-132, but grade 1/2 diarrhea was one of the most common adverse events.

Preliminary findings demonstrate a median progression-free survival of 8.1 months with 50% maturity, and a median overall survival of 10.8 months, with 79% of patients still alive.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD